News and Analysis | Published:

Alnylam prepares to land first RNAi drug approval

Nature Reviews Drug Discovery volume 17, pages 156157 (2018) | Download Citation

With Alnylam's rare disease drug candidate patisiran nearing the regulatory finish line, the RNA interference community is now turning its attention to next-generation delivery technology to solidify the future of the emerging modality.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2018.20

Authors

  1. Search for Chris Morrison in:

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing